Aurinia starts Phase 4 study combining Lupkynis with other lupus drugs

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/24/2026

1. GOOGL
2. TSLA
3. TXN
4. NOW
5. AMD
6. INTC
7. GOOG
8. CSX
9. IBM
10. KNX

Go back to Aurinia starts Phase 4 study combining Lupkynis with other lupus drugs
(NASDAQ: AUPH) Delayed: 15.24 -0.09 (0.59%)
Previous Close $15.33    52 Week High $5.69 
Open $15.11    52 Week Low $1.42 
Day High $15.37    P/E N/A 
Day Low $15.01    EPS $0.00 
Volume 675,893